Unknown

Dataset Information

0

Molecular Heterogeneity of Triple Negative Breast Cancer.


ABSTRACT: Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a unique biology. In this review we will discuss current and upcoming therapeutic strategies exploring novel approaches to targeted treatment of these TNBC subtypes.

SUBMITTER: Abramson VG 

PROVIDER: S-EPMC4235783 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Molecular Heterogeneity of Triple Negative Breast Cancer.

Abramson Vandana G VG   Mayer Ingrid A IA  

Current breast cancer reports 20140901 3


Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a uniq  ...[more]

Similar Datasets

| S-EPMC4641762 | biostudies-literature
| S-EPMC5913636 | biostudies-literature
| S-EPMC10842760 | biostudies-literature
2018-01-01 | GSE97342 | GEO
| S-EPMC4305416 | biostudies-other
| S-EPMC3962777 | biostudies-literature
| S-EPMC9381418 | biostudies-literature
| S-EPMC6911070 | biostudies-literature
| S-EPMC9735793 | biostudies-literature
| S-EPMC7113246 | biostudies-literature